PCSK9 Inhibition, Atherosclerotic Cardiovascular Disease and Health Economics: Challenges at the Crossroads

Improved survival following a cardiovascular event has led to an expanding patient population at very high risk of recurrent events. Reduction in low-density lipoprotein cholesterol, and thus implicitly non-high-density lipoprotein cholesterol, to guideline-recommended goals is a key tenet of secondary prevention. Yet, standard of care treatment with statin (with or without ezetimibe) often leaves a high risk of preventable cardiovascular events. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), highly efficacious lipid lowering treatments that confer reduction in cardiovascular events and death, clearly have a role in the personalized management of these very high-risk patients.

Source: Journal of Clinical Lipidology - July 23, 2019 Category: Lipidology Authors: Lieven Annemans, Jane K. Stock, M. John Chapman Tags: Review Article Source Type: research